Can a simple test predict your stroke risk? 7,000-Person study aims to find out.

NCT ID NCT06890702

Recruiting now Knowledge-focused Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study is looking for biological markers (biomarkers) in blood, urine, spinal fluid, and other samples that could help predict who will have a stroke and how they will recover. Researchers will follow 7,000 people with and without ischemic cerebrovascular disease for up to 4 years. The goal is to create a model that helps doctors diagnose and treat stroke earlier and more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple test to identify people at high risk for stroke before it happens, and help doctors choose the best treatment.
What could go wrong: This is an observational study, not a treatment trial. It may not find reliable biomarkers, and any findings will need years of further testing before they can be used in clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC CEREBROVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain ischemia cerebrovascular disorder ischemic stroke transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ISCHEMIC CEREBROVASCULAR DISEASE ISCHEMIC STROKE

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,
NOT_YET_RECRUITING

Wuhan, Hubei, 430030, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,
RECRUITING

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.